BRIEF-Bioxcel Receives Second Positive Recommendation To Continue Phase 3 Trial For Treatment Of Agitation Associated With Schizophrenia

Reuters

01 Jul

BRIEF-Bioxcel Receives Second Positive Recommendation To Continue Phase 3 Trial For Treatment Of Agitation Associated With Schizophrenia

July 1 (Reuters) - BioXcel Therapeutics Inc BTAI.O:

BIOXCEL THERAPEUTICS RECEIVES SECOND POSITIVE RECOMMENDATION FROM DATA SAFETY MONITORING BOARD (DSMB) TO CONTINUE SERENITY AT-HOME PIVOTAL PHASE 3 SAFETY TRIAL FOR ACUTE TREATMENT OF AGITATION ASSOCIATED WITH BIPOLAR DISORDERS OR SCHIZOPHRENIA
BIOXCEL THERAPEUTICS INC - TOPLINE DATA FOR SERENITY AT-HOME TRIAL EXPECTED IN Q3 2025
BIOXCEL THERAPEUTICS INC - DSMB RECOMMENDS CONTINUATION OF SERENITY AT-HOME TRIAL

Source text: ID:nGNXc8vy9N

Further company coverage: BTAI.O

(((( Reuters.briefs@thomsonreuters.com ;));))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2548003155"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2548003155\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2548003155?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-01 19:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2548003155","market":"us","top_or_hot":-1,"title":"BRIEF-Bioxcel Receives Second Positive Recommendation To Continue Phase 3 Trial For Treatment Of Agitation Associated With Schizophrenia","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Bioxcel Receives Second Positive Recommendation To Continue Phase 3 Trial For Treatment Of Agitation Associated With Schizophrenia</title></head><body><p><span>July 1 (Reuters)</span><span> - </span>BioXcel <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>BTAI.O</span>:</p><ul><li><p>BIOXCEL THERAPEUTICS RECEIVES SECOND POSITIVE RECOMMENDATION FROM DATA SAFETY MONITORING BOARD (DSMB) TO CONTINUE SERENITY AT-HOME PIVOTAL PHASE 3 SAFETY TRIAL FOR ACUTE TREATMENT OF AGITATION ASSOCIATED WITH BIPOLAR DISORDERS OR SCHIZOPHRENIA</p></li><li><p>BIOXCEL THERAPEUTICS INC - TOPLINE DATA FOR SERENITY AT-HOME TRIAL EXPECTED IN Q3 2025</p></li><li><p>BIOXCEL THERAPEUTICS INC - DSMB RECOMMENDS CONTINUATION OF SERENITY AT-HOME TRIAL</p></li></ul><p>Source text: <span>ID:nGNXc8vy9N</span></p><p>Further company coverage: <span>BTAI.O</span></p><p> (((( Reuters.briefs@thomsonreuters.com ;));))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Bioxcel Receives Second Positive Recommendation To Continue Phase 3 Trial For Treatment Of Agitation Associated With Schizophrenia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Bioxcel Receives Second Positive Recommendation To Continue Phase 3 Trial For Treatment Of Agitation Associated With Schizophrenia\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-01 19:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Bioxcel Receives Second Positive Recommendation To Continue Phase 3 Trial For Treatment Of Agitation Associated With Schizophrenia</title></head><body><p><span>July 1 (Reuters)</span><span> - </span>BioXcel <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>BTAI.O</span>:</p><ul><li><p>BIOXCEL THERAPEUTICS RECEIVES SECOND POSITIVE RECOMMENDATION FROM DATA SAFETY MONITORING BOARD (DSMB) TO CONTINUE SERENITY AT-HOME PIVOTAL PHASE 3 SAFETY TRIAL FOR ACUTE TREATMENT OF AGITATION ASSOCIATED WITH BIPOLAR DISORDERS OR SCHIZOPHRENIA</p></li><li><p>BIOXCEL THERAPEUTICS INC - TOPLINE DATA FOR SERENITY AT-HOME TRIAL EXPECTED IN Q3 2025</p></li><li><p>BIOXCEL THERAPEUTICS INC - DSMB RECOMMENDS CONTINUATION OF SERENITY AT-HOME TRIAL</p></li></ul><p>Source text: <span>ID:nGNXc8vy9N</span></p><p>Further company coverage: <span>BTAI.O</span></p><p> (((( Reuters.briefs@thomsonreuters.com ;));))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BTAI","symbol_name":"Bioxcel Therapeutics Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nTUA84CRSN:1","article_id":"2548003155","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2548003155","pubTimestamp":1751367964,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Bioxcel Receives Second Positive Recommendation To Continue Phase 3 Trial For Treatment Of Agitation Associated With SchizophreniaJuly 1 (Reuters) - BioXcel Therapeutics Inc BTAI.O:BIOXCEL THERA","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BTAI":"Bioxcel Therapeutics Inc.","BK4139":"生物科技"},"translate_title":"BRIEF-Bioxcel获得第二个积极建议，继续进行治疗精神分裂症相关激越的3期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BTAI":0.9},"content_text":"BRIEF-Bioxcel Receives Second Positive Recommendation To Continue Phase 3 Trial For Treatment Of Agitation Associated With SchizophreniaJuly 1 (Reuters) - BioXcel Therapeutics Inc BTAI.O:BIOXCEL THERAPEUTICS RECEIVES SECOND POSITIVE RECOMMENDATION FROM DATA SAFETY MONITORING BOARD (DSMB) TO CONTINUE SERENITY AT-HOME PIVOTAL PHASE 3 SAFETY TRIAL FOR ACUTE TREATMENT OF AGITATION ASSOCIATED WITH BIPOLAR DISORDERS OR SCHIZOPHRENIABIOXCEL THERAPEUTICS INC - TOPLINE DATA FOR SERENITY AT-HOME TRIAL EXPECTED IN Q3 2025BIOXCEL THERAPEUTICS INC - DSMB RECOMMENDS CONTINUATION OF SERENITY AT-HOME TRIALSource text: ID:nGNXc8vy9NFurther company coverage: BTAI.O (((( Reuters.briefs@thomsonreuters.com ;));))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}